Treatment Considerations in Cutaneous Melanoma: From Early Stage to Late/Advanced Stage

Access Activity

Overview / Abstract:

Jason J. Luke, MD, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability for patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management.

Expiration

Oct 25, 2024

Discipline(s)

Physician CME

Format

Webinar / Webcast / Video

Credits / Hours

0.5

Accreditation

ACCME

Presenters / Authors / Faculty

Jason J. Luke, MD, FACP
Hematology/Oncology
Associate Professor of Medicine
Director of Cancer Immunotherapeutics Center
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Sponsors / Supporters / Grant Providers

This activity is supported by an educational grant from Bristol Myers Squibb.

Keywords / Search Terms

Annenberg Center for Health Sciences at Eisenhower Overview, Burden of Disease,Molecular Targets,Perioperative Treatment Metastatic Treatment and Sequencing,Emerging Treatment Adverse Event Management Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map